![](/img/cover-not-exists.png)
THU0133 Results from A Phase 2A, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of Jnj-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Antirheumatic Drug Therapy
Genovese, M.C., Hsia, E., Belkowski, S., Chien, C., Masterson, T., Thurmond, R., Manthey, C., Yan, D., Ge, T., Greenspan, A.Volume:
73
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2014-eular.2404
Date:
June, 2014
File:
PDF, 186 KB
english, 2014